BridgeBio to Host Investor Call to Discuss Phase 2 Cohort 5 Data for Achondroplasia on March 6, 2023

Rhea-AI Summary

BridgeBio Pharma (Nasdaq: BBIO) announced an investor call on March 6, 2023, at 7:30 am ET to discuss Phase 2 Cohort 5 data from the PROPEL2 clinical trial of infigratinib, targeting achondroplasia. Infigratinib is designed to inhibit fibroblast growth factor receptor 3 (FGFR3), addressing a genetic condition affecting ~55,000 in the US and EU. This genetic disorder can lead to serious health complications, emphasizing the importance of continued research and treatment innovation. For more details, visit BridgeBio's website.

Positive

• Investor call scheduled to discuss promising Phase 2 Cohort 5 data.
• Infigratinib targets a significant unmet medical need in achondroplasia.

Negative

• None.

PALO ALTO, Calif., March 03, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will host an investor call on Monday, March 6 at 7:30 am ET to discuss Phase 2 Cohort 5 data from its PROPEL2 clinical trial of the investigational therapy infigratinib in children with achondroplasia. Infigratinib is an oral small molecule designed to inhibit fibroblast growth factor receptor 3 (FGFR3) and target achondroplasia at its source.

Achondroplasia is the most common cause of disproportionate short stature, affecting approximately 55,000 people in the United States (US) and European Union (EU), including up to 10,000 children and adolescents with open growth plates. Achondroplasia impacts overall health and quality of life, leading to medical complications such as obstructive sleep apnea, middle ear dysfunction, kyphosis, and spinal stenosis. The condition is uniformly caused by an activating mutation in FGFR3.

To access the live webcast, please visit the “Events” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 90 days following the event.

About BridgeBio Pharma, Inc.
BridgeBio Pharma (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn and Twitter.

BridgeBio Contact:
Vikram Bali
contact@bridgebio.com
(650)-789-8220

FAQ

What is the purpose of the PROPEL2 clinical trial for BBIO?

The PROPEL2 trial is examining the efficacy of infigratinib, targeting achondroplasia, a common genetic condition.

What are the implications of the Phase 2 data from the investor call on BBIO's stock?

Positive Phase 2 data could enhance investor confidence and potentially drive BBIO's stock price upwards.

When is the investor call regarding the PROPEL2 trial data?

The investor call will take place on March 6, 2023, at 7:30 am ET.

What impact does achondroplasia have on patients?

Achondroplasia can lead to serious health issues, including obstructive sleep apnea and spinal complications.